ELIMINATION OF DAIRY PROTEINS ISSUES OF DAIRY PROTEIN CONCENTRATES
The use of CRDSAt domain of human galectin-3 to remove lactosylated proteins from dairy concentrates addresses the Maillard reaction issues, achieving reduced browning and improved nutritional and organoleptic stability in dairy powders.
Patent Information
- Application Number
- FR2021012358
- Authority / Receiving Office
- FR · FR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-11-23
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing dairy powders suffer from non-enzymatic browning, nutritional loss, and organoleptic degradation due to the Maillard reaction, primarily driven by lactose content, which is not adequately addressed by existing methods.
A process using lectin, specifically the CRDSAt domain of human galectin-3, to selectively bind and remove lactosylated proteins from dairy protein concentrates, followed by lactose depletion, ensuring minimal lactose saturation and subsequent drying to produce lactose-depleted and lactosylated protein-free dairy concentrates.
The process effectively limits initial browning during drying and subsequent storage, enhances nutritional quality, and improves organoleptic stability by reducing the formation of advanced Maillard reaction compounds.
Smart Images

Figure 00000013_0000 
Figure 00000014_0000 
Figure 00000014_0001
Abstract
Description
Title of the invention: ELIMINATION OF LAC-TOSYLATED PROTEINS FROM DAIRY PROTEIN CONCENTRATES Technical field of the invention
[0001] The present invention relates to a process for removing lactosylated proteins from dairy protein concentrates, and to the product obtained by said process depleted in lactose and lactosylated proteins.
[0002] In the description below, the references in parentheses [ ] refer to the list of references presented at the end of the text. State of the art
[0003] Every year 650 million tons of milk are produced in the world. To ensure the conservation of milk and diversify its spectrum of uses, different industrial methods (for example: freeze-drying or atomization) make it possible to produce nearly 6 million tons of skimmed or whole milk powder per year in the world, particularly for infant nutrition.
[0004] Dairy powders are obtained following a series of unit steps, the first of which is the formulation of the concentrate: adjustment of proteins, lipids, minerals, lactose. Heat treatments are applied to ensure the microbiological quality of the product. Concentration operations (reduction of water content) and spray drying are then carried out to produce a dairy powder whose water activity is compatible with storage of the product at room temperature for several months.
[0005] Non-enzymatic browning via the Maillard reaction constitutes the main obstacle to the production and preservation of good quality milk powder, and occurs each time proteins are brought into contact with sugars with reducing functions. Thus lactose, present at a level of 5 g per 100 g of milk, is at the origin of the Maillard reaction, inducing browning of the milk powder, a nutritional loss (via the destruction of lysines, essential amino acids which react with lactose), and organoleptic modulations (via the products of the Maillard reaction).
[0006] It therefore appears to be clearly established to date that the lactose content in a milk protein matrix will influence the development of the Maillard reaction, and a fortiori on the browning of the powders. In this context, numerous studies illustrate the link between a reduction in lactose in milk protein powders and the limitation of their browning during storage.
[0007] Consequently, it is noted that there is still a need to produce dairy powders which do not have the disadvantages of the dairy powders of the prior art (i.e. browning, nutritional loss, organoleptic loss), even in the case of prolonged storage. Description of the invention
[0008] By carrying out a more detailed analysis of the browning of powders, the Inventors were the first to reveal that while reducing the amount of lactose reduces the initial browning of a powder upon drying, the extent of browning occurring during storage is not improved compared to the initial browning level of the powder (submitted article). Thus, reducing the lactose content of a dairy protein concentrate makes it possible (1) to limit the formation of lactosylated proteins during drying and (2) to limit the initial browning of the powder during drying, but has no impact on the development of browning during storage.Therefore, depleting a dairy protein concentrate in lactose and lactosylated proteins therefore makes it possible (1) to limit the initial browning of the powder during drying of the protein concentrate, but also (2) to limit the formation of reactive intermediates which will evolve towards advanced compounds of the Maillard reaction (AGE), and thus (3) to reduce the residual browning which takes place during storage.
[0009] The inventors have therefore demonstrated that if the lactose content is decisive for the level of browning of the powder induced by the initial stage of the Maillard reaction, the additional browning which occurs during storage is essentially independent of the lactose content.
[0010] In fact, if the lactosylation of lysines constitutes the first step of the Maillard reaction, once this lactosylation is initiated, it inevitably leads to a cascade of reactions ultimately leading to the production of brown pigments. The inventors hypothesized that by removing an essential intermediate, the degradation reactions could no longer take place.
[0011] The inventors are thus the very first to have demonstrated that during the aging of a milk powder, the development of the Maillard reaction depends more on the initial level of lactosylated proteins than on the lactose concentration in the powder, illustrating for the first time the harmful role of these lactosylated proteins during aging. In addition, during storage, the inventors have demonstrated that the lactosylated proteins detected are inversely proportional to the browning of the powder, which confirms that these proteins are indeed involved in the subsequent stages of the Maillard reaction (e.g. formation of advanced glycation end products (AGEs) and production of melanoidins). In this context, the inventors have developed a system for removing lactosylated proteins from milk protein concentrates with the aim of (1) limiting the browning of milk powders milk by reducing the Maillard reaction and its propagation during storage, (2) to improve the nutritional quality of milk powders by reducing the destruction of lysines, and (3) to promote better organoleptic stability of milk powders during their storage.
[0012] This technology constitutes the first method for eliminating lac-tosylated proteins from dairy protein concentrates responsible for the formation of intermediate or final compounds of the Maillard reaction (Heyns and Amadori compounds, hydroxymethylfurfural (HMF), malenoidins, etc.). This invention makes it possible to offer the general public products with better preservation and better nutritional and organoleptic properties. Indeed, the main dairy powder producing countries are located in particular in Europe and export their products to China, Africa or Indonesia for example. Since transport is most often by boat, it has been shown (readings from probes introduced into the cargoes) that temperature variations were experienced by the products.Since the Maillard reaction occurs very strongly during storage at high temperature and / or high humidity, this technology constitutes an effective means of preventing the degradation of powders when such storage must be carried out.
[0013] To successfully remove lactosylated proteins from dairy protein concentrates, the technology developed was essentially based on the use of a lectin, a family of proteins with the common property of interacting with sugars. In particular, human galectin-3 (GAL-3), and more particularly its C-terminal domain called CRDSAt, which has the ability to interact specifically with lactose, as well as its lactosylated and N-acetyl-lactosylated derivatives. This CRDsat protein was described in International Application WO 2017 / 194888) [1].
[0014] According to one embodiment, the technological process then takes place in 3 stages. (1) Reduction of the free lactose content of the dairy protein concentrates (in order not to saturate the binding sites of the CRDSAt protein) which can be carried out by any method known to those skilled in the art, for example according to the following 3 effective approaches: (i) diafiltration on a 3 kDa or 10 kDa membrane, (ii) gel filtration via the use of a desalting / buffer exchange type chromatography column (e.g. size exclusion chromatography of molecules with a molecular mass lower than 3 kDa or 5 kDa), and (iii) the use of a lactase type enzyme to cleave the free lactose into glucose + galactose. (2) Incubation of the dairy protein concentrate with a support (e.g. a chromatography resin) on which the CRDSAT protein is immobilized (CRD support, e.g.CRD resin) whose three-dimensional “all-[3 fold” structure is synonymous with high protein stability. Retention of lactosylated proteins in a single step is made possible due to the very high affinity of CRDSAT for them. Then drying of the protein concentrate. dairy in the absence of lactose and lactosylated proteins. (3) Regeneration of the CRD support (CRD resin) by a lactose solution and extensive washing, for its reuse for the preparation of a new dairy protein extract.
[0015] The present invention therefore relates to a process for removing lactosylated proteins from an initial dairy protein concentrate, said process comprising: a) at least one step of lactose depletion of the starting milk protein concentrate to form a lactose-depleted milk protein concentrate; b) a step of incubating the lactose-depleted milk protein concentrate from step a) on a support grafted with a lectin or a part of lectin binding the lactosylated proteins, and of retaining the lactosylated proteins on said support; c) a step of recovering the eluate comprising or consisting of the dairy protein concentrate depleted in lactose and lactosylated proteins from step b).
[0016] For the purposes of the present invention, the term "initial milk protein concentrate" means a milk protein concentrate: MPC (Milk Protein Concentrate), MPI (Milk Protein Isolate), WPI (Whey Protein Isolate), PPCN (Native Phosphocaseinates), or caseinates. Such milk protein concentrates may comprise very variable lactosylated protein contents depending on the type of proteins contained (caseins, soluble proteins), the origin of the milk, its storage time before concentration / drying, and the heat treatments already undergone (Illustration case in Example 1 (see below): the milk protein concentrate initially contained 27% of [3-lactoglobulin in lactosylated form).
[0017] For the purposes of the present invention, the term "lactose-reduced milk protein concentrate" means a concentrate whose initial lactose content is between 1 and 10%, and whose content is further reduced by step a) by at least 50% relative to the content of the initial milk protein concentrate, preferably a lactose content reduced by 80% to 99% relative to the content of the initial milk protein concentrate. For example, a lactose-reduced milk protein concentrate initially comprising from 1 to 10% lactose will have a concentration reduced to 0.5-5% lactose, preferably less than 1% lactose.
[0018] For the purposes of the present invention, the term "support" means any support capable of covalently binding the lectin or the lectin portion binding the lactosylated proteins. For example, the grafting support of step b) is chosen from the group consisting of celluloses, polysaccharides, organic or inorganic supports, minerals (SiO2), glass; in the form of resins, beads, pearls, blocks, threads, fabrics, the surface of which may or may not be porous. For example, if it is a chromatography resin, the lectin-resin coupling can be carried out on a resin of the CNBr (Cyanogen Bromide) Sepharose (Cytiva®) type, or NHS (N-hydroxysuccinimide) Sepharose (Cytiva®), or NHS (N-hydroxysuccinimide) agarose (Pierce®).
[0019] According to a particular embodiment of the process according to the present invention, said process further comprises a step d) of drying the dairy protein concentrate depleted in lactose and lactosylated proteins from step c).
[0020] According to a particular embodiment of the process of the present invention, step a) is carried out by at least one diafiltration on a 3 kDa or 10 kDa membrane and / or a steric exclusion chromatography of molecules with a molecular mass of less than 3 kDa or 5 kDa and / or the use of a lactase-type enzyme in order to cleave the free lactose.
[0021] According to a particular embodiment of the method according to the present invention, the lectin or part of lectin grafted onto the support used in step b) is a galectin or part of galectin binding lactosylated proteins, preferably human galectin-3 or part of human galectin-3 binding lactosylated proteins. Preferably, the part of human galectin-3 comprises or consists of the CRDSAt domain of sequence SEQ ID NO: 1 (MSATGAYPA TGPYGAPAGP LIVPYNLPLP GGVVPXx MLIT ILGTVKPNAN RIALDFQRGN DVAFHFNPRF NENNRRVIVC NTKLDNNWGR EERQSVFPFE SGKPFKIQVL VEPDHFKVAV NDAHLLQYNH RVKKLNEISK LGISGDIDLT SX2SYTMI; where X! is R or K and / or X2 is A or T).
[0022] According to a particular embodiment of the process according to the present invention, the support is regenerated at the end of step b) with a lactose solution then extensive washing in a buffer at the pH of the milk extract (generally pH=6.8, totally compatible with the CRD).
[0023] The present invention also relates to a dairy protein concentrate obtained by the process according to the present invention, characterized in that said dairy protein concentrate comprises a reduced lactose content and a reduced proportion of lactosylated proteins, compared to those of the initial dairy protein concentrate. In particular, the dairy protein concentrate according to the present invention has a lactosylated protein content reduced by at least 50% compared to the content of the initial dairy protein concentrate, preferably a lactosylated protein content reduced by 50% to less than 100% compared to the content of the initial dairy protein concentrate.In particular, the dairy protein concentrate according to the present invention has a lactose content reduced by at least 50% compared to the content of the initial dairy protein concentrate, preferably a lactose content reduced by 80% to 99% compared to the content of the initial dairy protein concentrate. For example, a dairy protein concentrate according to the present invention has a lactose content of 0.5-5%, preferably less than 1%.
[0024] The milk protein concentrate obtained by the process according to the present invention makes it possible to delay the browning of milk protein powders, and thus limits all of the undesirable effects due to the Maillard reaction and the browning of powders during storage. BRIEF DESCRIPTION OF THE FIGURES
[0025] [Fig.l] represents the capture of lactosylated proteins from milk concentrate by chromatography on resin coupled with the CRDSat domain of human galectin-3 (wells 4 and 6) after prior elimination by PD 10 exclusion chromatography (wells 1 to 2): 1: INP av PD 10: Protein fraction before elimination of lactose by PD 10; 2: INP ap PD10: Protein fraction after elimination of lactose by PD10; 3: FT T-: milk proteins not retained on virgin resin; 4: FT CRD: milk proteins not retained on resin coupled with CRDSat; 5: Elution T-: proteins released from the virgin resin after elution with 100 mM lactose; 6: Elution lactose: proteins released from the CRDSAt resin after elution with 100 mM lactose.
[0026] [Fig.2] represents the level of protein lactosylation measured by high pressure liquid chromatography coupled with mass spectrometry (LC-MS) analysis and the relative quantification of native and lactosylated forms of [3-lactoglobulin (B-LG). (A) quantification of native and lactosylated forms as the protocol progresses. (B) lactosylation of initial B-LG (C) lactosylation of B-LG after removal of lactosylated proteins. (D) lactosylation of B-LG retained on CRD beads.
[0027] [Fig.3] represents the interaction specificity of the CRDSAt domain for lactosylated proteins. 1: INP av PD 10: Protein fraction before lactose removal by PD 10; 2: FT CRD: milk proteins not retained on CRDSAt beads; 3: Lactose elution: proteins bound on CRDSAt resin after elution with 100 mM lactose; 4: Milk glycoproteins: Bovine milk glycoproteins; 5: Negative control: soybean trypsin inhibitor (purified non-glycosylated protein); 6: Positive control: Horseradish peroxidase (purified highly glycosylated protein). EXAMPLES EXAMPLE 1: PROCESS FOR ELIMINATION OF LAC-TOSYLATED PROTEINS FROM MILK PROTEIN CONCENTRATES
[0029] Dairy protein concentrates are generally composed of 20 to 30% dry matter, and consist mainly of protein and lactose. Both protein and lactose are present at concentrations in the millimolar (mM) range in the concentrate.
[0030] For the purposes of the experiment, a milk protein powder with an 80 / 20 ratio (caseins / serum proteins) representative of the protein proportions of bovine milk was used. This powder has a proportion of lactosylated proteins due to the pre-treatments (heat treatments, vacuum evaporation (concentration)) applied to the milk concentrate. Elimination of lactose
[0031] The elimination of lactose is required to avoid saturating the binding sites of the CRDSat domain of human galectin-3.
[0032] The first method consisted of removing lactose by diafiltration, and relied on the use of a Stirred Cell type device (Millipore). The concentrate was placed in a reactor on a regenerated cellulose membrane with a cut-off of 3 kDa. The molar mass of a lactose molecule being 342 Da, the lactose crossed the diafiltration membrane thanks to a flow of nitrogen pushing the liquid under the membrane. Proteins larger than 3 kDa were therefore all retained above the filter.
[0033] The second method was based on the use of a HiTrap Desalting (GE) or PD-10 Desalting (GE) type chromatography column. The molecules present in the concentrate passed through the column according to their masses and made it possible to eliminate molecules smaller than 5000 Da, therefore lactose.
[0034] Both of the above methods were very effective in removing lactose, with the gel filtration method being faster than the diafiltration method (20 minutes vs. 4 hours, respectively) being preferred.
[0035] A third method is based on the use of a lactase-type enzyme to cleave free lactose into glucose + galactose. Elimination of lactosylated proteins
[0036] The CRDSAt domain was produced in the form of a purified recombinant protein in E. coli. Its attachment to an NHS activated (Pierce) type resin (CRD resin) was more than 65% efficient, which is a very good yield for this type of grafting.
[0037] The immobilization of a CRDSat molecule on the resin (CRD resin) therefore made it possible to retain approximately 1 g of lactosylated proteins. Obtaining milk powders free of lactosylated proteins - depending on the subsequent applications and needs - made it possible to increase the yield.
[0038] The CRD resin was used either in an open system for so-called "batch" purifications, or in "packed" mode in a chromatography column. The concentrate was brought into contact with the CRD resin which retained the lactosylated proteins.
[0039] After separation of the CRD resin, the concentrate was then ready to be dried.
[0040] On an SDS-PAGE gel illustrating the steps of carrying out the experiment, 15 pg of proteins were deposited, before and after elimination of lactose ([Fig.l] by gel filtration, lanes 1 and 2). This step did not induce any specific retention of proteins. The milk, depleted in lactose, was deposited after being put in contact with a control resin (T- resin, [Fig.l], lanes 3) or a CRD resin ([Fig.l], lane 4). For identification, the lactosylated proteins retained by the CRDSat domain were eluted from the resins and deposited at constant volume ([Fig.l], lanes 5 and 6). This revealed that the virgin resin retains very few proteins nonspecifically (lane 5), and that most of the proteins can be lactosylated during the various unit operations carried out during the powder manufacturing process and were efficiently retained on the CRD resin (lane 6).
[0041] The proportion of lactosylated proteins was monitored by LC-MS mass spectrometry by following the lactosylation of [3-lactoglobulin] ([Fig.2]). The analysis revealed that the milk sample placed in contact with the CRD resin contains at least 2 times less lactosylated proteins than initially (Figure 2A, B, C). Thus, for this test, the milk sample went from 27% to only 13% of lactosylated proteins. The analysis of the B-LG retained on the CRD resin showed a very large enrichment in lactosylated proteins (Figure 2D). The immobilization of the lactosylated proteins on the CRD resin was therefore effective since it made it possible, from the first tests, to eliminate more than 50% of the lactosylated proteins. This yield can be further increased by passing the sample through the column several times to reduce the concentration of lactosylated proteins.
[0042] The interaction specificity of the CRDSat domain for lactosylated proteins was tested by staining the proteins retained on the CRD resin with periodic acid / fushine to stain the glycosylated proteins. The protein profile (Coomassie blue staining, [Fig. 3], left) was different between a mixture of glycosylated milk proteins (lane 4) and the proteins retained by the CRDSAt domain (lane 3), supporting the observation that the CRDSAt domain did not retain naturally glycosylated milk proteins. This was confirmed by periodic acid / fushine staining ([Fig. 3], right). This method allowed the detection of glycosylated proteins by reacting with the vicinal diols of sugars present on the glycosylated proteins. Lane 4, a strong signal corresponded to glycosylated milk proteins.Lanes 1 and 2, glycosylated proteins were not sufficiently enriched to be detected with this method. Lane 3, since lactose is only a diholoside, this method was not sensitive enough to detect lactosylated proteins, confirming that the CRDSAt domain is indeed specific for lactosylated proteins. CRD resin regeneration
[0043] The CRD resin was regenerated with a lactose solution and then by extensive washing in a buffer at the pH of the milk extract (generally, pH=6.8, fully compatible with the CRDSAt domain) - List of references
[0044] 1. International application WO 2017 / 194888
Claims
Claims
1. A method for removing lactosylated proteins from an initial dairy protein concentrate, said method comprising: a) at least one step of depleting lactose from the initial dairy protein concentrate to form a lactose-depleted dairy protein concentrate; b) a step of incubating the lactose-depleted dairy protein concentrate from step a) on a support grafted with a lectin or a portion of lectin binding the lactosylated proteins, and retaining the lactosylated proteins on said support; c) a step of recovering the eluate comprising the lactose- and lactosylated protein-depleted dairy protein concentrate from step b).
2. Method according to claim 1, said method further comprising a step d) of drying the dairy protein concentrate depleted in lactose and lactosylated proteins resulting from step c).
3. Method according to claim 1 or 2, wherein step a) is carried out by at least one diafiltration on a 3 or 10 kDa membrane and / or a size exclusion chromatography of molecules with a molecular mass of less than 3 or 5 kDa and / or a lactase-type enzyme.
4. Method according to any one of claims 1 to 3, where the grafting support of step b) is chosen from the group consisting of celluloses, polysaccharides, organic or inorganic supports, minerals, glass; in the form of resins, beads, pearls, blocks, threads, fabrics, the surface of which may or may not be porous.
5. A method according to any one of claims 1 to 4, wherein the lectin or lectin portion is a galectin or galectin portion binding lactosylated proteins.
6. The method of claim 5, wherein the galectin or part thereof is human galectin-3 or part thereof binding lactosylated proteins.
7. The method of claim 6, wherein the portion of human galectin-3 comprises or consists of the CRDSAt domain of sequence SEQ ID NO:
1.
8. Dairy protein concentrate obtained by the process according to any one of claims 1 to 7, characterized in that said dairy protein concentrate comprises a reduced lactose content. of at least 50% compared to the lactose content of 1-10% of the initial milk protein concentrate and a lactosylated protein content reduced by at least 50% compared to the lactosylated protein content of 27% of the initial milk protein concentrate.
